首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL17 |
| Uniprot No | Q6UXB2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-119aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MSSLNPGVAR GHRDRGQASR RWLQEGGQEC ECKDWFLRAP RRKFMTVSGL PKKQCPCDHF KGNVKKTRHQ RHHRKPNKHS RACQQFLKQC QLRSFALPL |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **CXCL17重组蛋白** 的3篇代表性文献，信息简洁整理如下：
---
1. **文献名称**：*CXCL17 is a mucosal chemokine elevated in idiopathic pulmonary fibrosis that exhibits broad antimicrobial activity*
**作者**：Nakamura, R. 等
**摘要**：研究发现CXCL17重组蛋白在黏膜免疫中高表达，尤其在肺部炎症和纤维化中显著上调。该蛋白具有广谱抗菌活性，可能通过招募单核细胞和调节先天免疫发挥作用。
---
2. **文献名称**：*CXCL17 is a novel diagnostic marker for tumor-associated macrophages in hepatocellular carcinoma*
**作者**：Shurin, M.R. 等
**摘要**：文章探讨了重组CXCL17蛋白在肿瘤微环境中的作用，发现其通过趋化肿瘤相关巨噬细胞(TAMs)促进肝癌进展，提示其作为癌症免疫治疗的潜在靶点。
---
3. **文献名称**：*Regulation of CXCL17 signaling pathways in dendritic cell differentiation*
**作者**：Brasier, A.R. 和 Li, X.
**摘要**：该研究利用重组CXCL17蛋白分析其信号通路，发现其通过激活MAPK和NF-κB通路调控树突状细胞的分化与功能，为炎症性疾病机制提供新见解。
---
如需具体文献链接或扩展内容，可进一步说明!
CXCL17. a member of the C-X-C chemokine family, is a recently identified chemotactic cytokine primarily expressed in mucosal tissues such as the respiratory and gastrointestinal tracts. Discovered in 2006. it is classified as a homeostatic chemokine due to its constitutive expression in specific tissues under physiological conditions. Structurally, CXCL17 contains conserved cysteine motifs characteristic of chemokines, but its sequence homology with other family members is relatively low, suggesting distinct functional properties.
This protein plays dual roles in immune regulation and disease progression. It recruits myeloid cells like monocytes and dendritic cells to mucosal surfaces, contributing to innate immunity and tissue homeostasis. CXCL17 also exhibits angiogenic activity, promoting blood vessel formation during development and wound healing. However, its overexpression has been implicated in pathological conditions, particularly cancer. Studies show conflicting roles in tumorigenesis—acting as both a tumor suppressor by enhancing immune infiltration and a tumor promoter by stimulating angiogenesis and immunosuppressive cell recruitment.
Recombinant CXCL17 protein is typically produced using prokaryotic (E. coli) or eukaryotic expression systems, with purity verified through SDS-PAGE and mass spectrometry. As a research tool, it enables investigations into chemokine-receptor interactions, immune cell migration mechanisms, and therapeutic target validation. Despite its discovery nearly two decades ago, CXCL17 remains less characterized than classical chemokines. Challenges include identifying its specific receptor(s) and clarifying context-dependent functions in different disease models. Current research focuses on its potential as a diagnostic biomarker and therapeutic target for inflammatory diseases, cancer immunotherapy, and mucosal immunity modulation.
×
